We are excited to share that Jennifer Che, President and Managing Director of Eagle IP, will be attending the Life Sciences Patents Network (LSPN) North America Spring conference, held from April 29–30, 2026, at the Hyatt Regency Boston.

As a premier gathering for the global biopharma and medtech communities, LSPN Boston provides a vital platform for IP leaders to discuss the strategies and legal frameworks driving innovation in the life sciences. With her extensive background as  a medicinal chemist, US Patent Attorney, and Managing Director of a team of Chinese patent attorneys, Jennifer is uniquely positioned to engage with industry peers on the complex IP challenges, especially with respect to Asia, facing modern biotech companies.

If you are attending LSPN Boston and would like to discuss global IP strategy or specific developments in the Asian markets, Jennifer would welcome the opportunity to connect. Please contact us to schedule a meeting during the conference.

我们的过去活动

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Eagle IP to Participate in AIPLA 2026 Spring Meeting in San Francisco

2026年5月8日

Eagle IP has been named as the Winner of the LSPN Cross-Border Collaboration Partner of the Year Award at the LSPN Awards USA 2026

2026年5月8日

Eagle IP to Attend INTA 2026 Annual Meeting in London

2026年5月2日

Recommended Insights

China Releases Draft Examination Guidelines for the new Patent Law

2020年12月4日
The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]
阅读更多 >

Stealing Trade Secrets: How the Chinese Court Criminally Sentences Employees that Steal Trade Secrets - 2019 China’s Top 50 Representative IP Cases

2020年6月11日
The theft of trade secrets has always been a deep concern of foreign companies thinking of doing business in China, whether it be sharing protocols with a manufacturing partner, providing technology details to a potential investor, or sharing results from an R&D collaboration. How can businesses ensure that employees do not steal secrets and share […]
阅读更多 >

Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment

2020年7月10日
Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]
阅读更多 >

First ever Invalidation decision on an RNAi Invention patent in China

2023年12月4日
Decision on Examination of Request for Invalidation (No. 58530) In one of China’s Top 10 Patent Re-examination / Invalidation cases of 2022, an invalidation decision on a patent claiming Hepatitis B Virus (HBV) RNAi compositions (No. 58530) by the Patent Re-examination Board (the “Board”) sheds light on the standard for post filing data for rejections […]
阅读更多 >
Top crossarrow-right